Prader-Will Syndrome Market Insights, Epidemiology Segmentation, and Market Report Scope 2032

DelveInsight’s Prader-Will Syndrome Market Insights report provides a thorough understanding of current treatment practices, emerging drugs, Prader-Will Syndrome market share of the individual therapies, current and forecasted Prader-Will Syndrome market size from 2019 to 2032 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).


Prader-Will Syndrome Overview

Prader-Willi syndrome is a complex genetic condition that affects many parts of the body. This condition is characterized by weak muscle tone (hypotonia), feeding difficulties, poor growth, and delayed development in infancy. Beginning in childhood, affected individuals develop an insatiable appetite, which leads to chronic overeating (hyperphagia) and obesity. Some people with Prader-Willi syndrome, particularly those with obesity, also develop type 2 diabetes (the most common form of diabetes).


Download Prader-Will Syndrome Market sample report @


Some of the key features of the Prader-will syndrome market report

Approximately 65%–70% of the PWS cases are due to the deletion of paternal genes on chromosome 15 in the 15q11-q13 region, 20%–30% are caused by a maternal uniparental disomy of chromosome 15 and most of the remaining 2%–5% have an imprinting centre defect or unbalanced translocations.
Prevalence rates for Prader-Willi syndrome range from 1 per 16,000 population in western Japan.
Prader-Willi syndrome (PWS), prevalence has been variously quoted as “about 1 in 25 000 live births.
Prader–Willi syndrome (PWS) is a rare genetic disorder with a birth incidence of 1/10,000 to 1/30,000, and an estimated prevalence of approximately 10,000 to 20,000 living individuals in the United States. It affects males and females equally, as well as all races and ethnicities
Prader-will syndrome companies are included like Soleno Therapeutics Inc, Levo Therapeutics, and many others.
Prader-will syndrome therapies are included like Diazoxide Choline Controlled-Release (DCCR), LV-101, and many others.


Prader-Will Syndrome Market Disease

The disease occurs due to the loss of function of several genes in a particular region of chromosome number 15. Among these are genes that provide instructions for making molecules called small nucleolar RNAs (snoRNAs).


Prader-Will Syndrome Causes

Prader-Will syndrome (PWS) is the first syndromic form of the neurodevelopmental disorder that was confirmed to be caused due to imprinting errors leading to a multisystem genetic disorder characterized during infancy by lethargy, diminished muscle tone (hypotonia), feeding difficulties, poor weight gain and growth hormone deficiency.


Prader-Will Syndrome Treatment

The treatment of PWS is currently based on treating the symptoms of the disorder as they arise. Growth hormone deficiency is present in almost all children and many adults with PWS. In multiple studies, human growth hormone (HGH) has been found to be beneficial for those with Prader-Willi syndrome. In June of 2000, HGH was officially approved by the Federal Drug Administration (FDA) in the United States for use in patients with Prader-Willi syndrome. HGH is effective not only in increasing height, but also in decreasing body fat, increasing muscle mass, improving weight distribution, increasing stamina, and increasing bone mineral density. Some of the major approved GH therapies include Pfizer’s Genotropin (somatropin) along with other major brands such as Norditropin (Novo Nordisk) and a few others in the US.


Request a sample and discover more about the report offerings @


Prader-Will Syndrome Epidemiology Segmentation in the 7MM

Prevalent Cases
Diagnosed Cases
Mutation Types
Associated Clinical Manifestation


Prader-Will Syndrome Emerging Drugs Analysis

Key players such as Levo Therapeutics (LV-101), Harmony Biosciences (Pitolisant), Soleno Therapeutics (Diazoxide Controlled Release [DCCR]; Lipidio Pharmaceuticals [GDD3898]), and many others are involved in developing therapies for Prader-Willi Syndrome (PWS).


Prader-Will Syndrome Market Drivers

Increase in research activities
Increasing disease prevalence
Surge in a number of clinical studies


Prader-Will Syndrome Market Barriers

Treatment costs
Need for novel therapeutics
Entry of biosimilars


Prader-Will Syndrome Market Report Scope

Study Period: 2019-2032
Coverage: The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan
Key Prader-Will Syndrome companies: Soleno Therapeutics Inc, Levo Therapeutics, and many others.
Key Prader-Will Syndrome Therapies: Diazoxide Choline Controlled-Release (DCCR), LV-101, and many others.
Unmet Needs
KOL’s views
Market Access


For further information on Prader-Will Syndrome Market @


Table of Content

1. Key Insights

2. Executive Summary of Prader-Willi Syndrome

3. Competitive Intelligence Analysis for Prader-Willi Syndrome

4. Prader-Willi Syndrome: Market Overview at a Glance

5. Prader-Willi Syndrome: Disease Background and Overview

6. Patient Journey

7. Prader-Willi Syndrome Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Prader-Willi Syndrome Unmet Needs

10. Key Endpoints of Prader-Willi Syndrome Treatment

11. Prader-Willi Syndrome Marketed Products

12. Prader-Willi Syndrome Emerging Therapies

13. Prader-Willi Syndrome: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Prader-Willi Syndrome

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight


Get in touch with our Business executive @


About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States